Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IRO-203
- Development stage
- Unknown
- Lead developer
- DNAVEC
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intranasal
01
Overview
IRO-203 is an intranasal COVID-19 vaccine candidate developed by ID Pharma Co., Ltd., a subsidiary of I'rom Group. It utilizes a non-transmissible Sendai virus (SeV) vector to deliver the genetic sequence of the SARS-CoV-2 spike protein. Administered intranasally, the vaccine is designed to induce both systemic immunity (IgG) and local mucosal immunity (IgA) in the respiratory tract, which is the primary site of viral entry. This approach aims to provide a more effective barrier against infection and transmission compared to traditional intramuscular vaccines. IRO-203 is currently being evaluated in Phase 1 clinical trials in Japan as a booster dose for healthy adults who have previously received primary COVID-19 vaccinations.
- Other names
- Intranasal SeV-vector COVID-19 vaccineSendai virus vector COVID-19 vaccineSeV-vector COVID-19 vaccinenT-SeV-vector COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on IRO-203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IRO-203.